Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm curious who knew earnings release this morning?
ouch!...bad news...back to 8...
HUGE NET LOSS > Vaxart reported a net loss of $16.0 million for the first quarter of 2021
compared to $1.3 million for the first quarter of 2020. Net loss per
share for the first quarter of 2021 was $0.14, compared to a net loss of
$0.02 in the first quarter of 2020. The increase in net loss per share
was due to the increase in net loss partially offset by the increase in
the weighted average number of shares outstanding.
-- Revenue for the first quarter of 2021 was $506,000 compared to $2.9
million in the first quarter of 2020. The decrease was principally due to
a reduction in royalty revenue related to Inavir sales in Japan as a
result of abnormally low incidences of seasonal influenza.
-- Research and development expenses were $10.1 million for the first
quarter of 2021 compared to $1.5 million for the first quarter of 2020.
The increase was mainly due to manufacturing and clinical trial expenses
related to the COVID-19 and norovirus vaccine candidates.
-- General and administrative expenses were $5.9 million for the first
quarter of 2021 compared to $2.0 million for the first quarter of 2020.
The increase was mainly due to higher legal and insurance expenses, and
an increase in headcount and related costs.
VXRT$ premarket looks good....let's see what data they release...$15 to 16 likely today.
I didn’t say the results were bad. Indeed they were misinterpreted by many including the media so they dropped.
It was everything as you said and agree an buying opportunity which I did.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161616491
The results weren’t bad. They were misinterpreted. Their delivery system wasn’t meant to produce antibodies like the injectable vaccines did. The pill was supposed to induce an immune response which it did. The data was very good actually. The media and investors just focused on the fact that no antibodies were created and ignored the fact that creating antibodies was never the goal for this vaccine. If anything the drop was just a buying opportunity.
In order to run the data has to be good. This stock dropped earlier by the results.
See the Motley Fool article of April 30th: https://www.fool.com/investing/2021/04/30/why-vaxart-stock-is-soaring-today/ . Besides mentioning the info in the press release it says "Additionally, Vaxart has become increasingly popular among traders on Reddit and other social media platforms in recent weeks. This is no doubt amplifying the moves in its stock price, which is likely to remain volatile."
See also https://scrip.pharmaintelligence.informa.com/SC144270/Your-Annual-COVID-19-Vaccine-Booster-Could-Be-A-Pill-Or-A-Spray which says in part the following:
'In addition to convenience, oral and nasal vaccine candidates have other potential advantages in that they elicit immune response in a different way to subcutaneous or intramuscular vaccines.
In subcutaneous or intramuscular vaccines, the primary immune response is systemic humoral immunity, in which B-cells generate antibodies (IgG) against the pathogen in the blood. They tend to produce limited cellular immunity from T-cells, and only weak protection at the mucosal surfaces, which include the nasal cavity and the stomach.
The reverse is true with oral and nasal vaccines – delivering a vaccine via mucosal surfaces generates mucosal antibodies (IgA) as well as a T-cell response, while systemic antibody response (IgG) can be limited.
A vaccine that could provide a mucosal immune response in the nose and mouth is likely to be preferable against an airborne respiratory virus like SARS-CoV2, as it would provide a barrier at the infection site.
Vaxart and Altimmune have both made progress in the last 12 months for their respective oral and nasal drug delivery platforms, and they see applications for their products across a range of infectious diseases.
A Phase II head-to-head challenge study of Vaxart’s oral flu vaccine candidate versus Sanofi’s Fluzone shot and a placebo showed superior efficacy to Sanofi’s established product. Illness rates were 39% lower in those given Vaxart’s oral vaccine compared with unvaccinated subjects, and 27% lower than in those vaccinated with Fluzone.
The trial was funded by the US Biomedical Advanced Research and Development Authority (BARDA) and was published in the Lancet Infectious Diseases in January 2020.
The results also showed that Vaxart’s vaccine generated less than one tenth of the serum neutralizing antibodies of the injectable product, yet it protected as well. This illustrated the importance of the T cell immunity, as well as the small but significant levels of mucosal antibodies generated.
Explaining the mechanism on a HC Wainwright & Co investor call in March, Vaxart’s founder and chief scientific officer Sean Tucker said: “A little bit of mucosal B-cells goes a long way”.
...
Vaxart believes its approach of targeting two of the virus’ proteins could be another key differentiator for its vaccine as the N protein is more conserved than the S protein, and therefore could hold out against new SARS-CoV2 variants.
This theory has yet to be clinically tested, but the candidate has passed the first hurdle, with preliminary Phase I trial data meeting its primary and secondary endpoints, with no reports of severe adverse indications.
As in the flu trial, the vaccine generated CD8+ cytotoxic T-cell responses in a majority of patients that may provide long lasting memory, proinflammatory Th1 cytokines and IgA responses, and elevated mucosal homing receptors for B-cell immune response.
The company is now gearing up for Phase IIa immunogenicity and dose-ranging study in Q2, which once complete, will immediately be followed by a Phase IIb efficacy study.
Vaxart’s founder and chief scientific officer Sean Tucker said the world could be stuck on a ‘hamster wheel’ trying to constantly update injected vaccines that target a mutating S protein.
He believes its approach of targeting the N and S proteins with an oral vaccine could tackle emerging variants of concern.
“The best way to do that is essentially hand out tablets because then you don't have to line up and wait for the syringes to go into people's arms.”
Highlighting the benefits of targeting the N protein he said: “The South African strain that everybody's concerned about has only one amino acid difference in the N protein compared to the original Wuhan, so it's again a very well conserved target…for T-cells.” '
If data is great...this will jump to 20+ ...was in this ticker last year. What a wild roller coaster ride it was. Got in Friday and adding premarket less than 12 and exit at 17-20 strategy
In addition to what Ursa said in post #6014, the press release said "The Company will also present new mucosal antibody data and review the recent Phase I clinical results that suggest VXA-CoV2-1 is potentially protective against new and emerging COVID-19 strains."
The pr said T cell data will be released ...this is going to run this week...
https://investors.vaxart.com/news-releases/news-release-details/vaxart-host-key-opinion-leader-webinar-importance-t-cell
Why do you think we will see results next week?
They're not going to have results for a long time.
I've been thinking that also, and if it happens I am ready to profit from it.
If results are promising this will run to 20 to 30 next week....
I also think it sounds it encouraging. Instead of focusing on the systemic antibodies that vaccines by injections focus on, VXRT (for its Covid-19 vaccine) seems to be focusing on mucosal antibodies as well as T-cell responses.
wow! seems they made progress...Monday may see 40 to 60% gain...let's see
First there is the press release issued on April 26th (https://investors.vaxart.com/news-releases/news-release-details/vaxart-host-key-opinion-leader-webinar-importance-t-cell ) in which VSRT said the webinar (to begin on Monday at 12 noon ET) will "... report on the importance of T-cell immunity in COVID-19 vaccines ..." and in which VXRT said "Vaxart's management will provide new data comparing the T-cell responses generated from its VXA-CoV2-1 vaccine with those of other vaccines. The Company will also present new mucosal antibody data ...."
Second there is the press release issued on April 29th (https://investors.vaxart.com/news-releases/news-release-details/vaxart-present-world-vaccine-congress-washington-2021 ) in which VXRT said "... its founder and chief scientific officer, Sean Tucker, Ph.D., will present" (about the "Vaxart oral COVID-19 vaccine") "at the upcoming World Vaccine Congress Washington that will be held virtually from May 4-6, 2021".
The Motley Fool article touting a 100% gain likely helped. That's been realized, now, so 50-50 on more.
Would be great to have a pill, but there's zero evidence they have one that works.
heard partnership
Why is this going up.....last I checked was their vaccine failed to produce antibodies...anyone can update the situation...
I lost in the last crash...hopefully this can see 17 or 20
* * $VXRT Video Chart 04-30-2021 * *
Link to Video - click here to watch the technical chart video
Great article! Flu vaccine!
I agree! Get the pill!
The Vaxart pill will likely offer broader protection as well because it protects the mucous system!
$VXRT I’m out made some nice coin here. Thank you
Is that a proven fact? The only thing I can remember about Covaxin is that there’s a 81% efficacity.
Unless you get the Covaxin booster shot which will give you lifetime immunity
Each year you will need a Covid shot like a yearly flu shot. Wouldn't you rather take pills each year? Also, pills are stable at room temperature and can be shipped to many countries and to people in remote locations. If this works, then this is a goldmine IMO. GLTA.
* * $VXRT Video Chart 04-29-2021 * *
Link to Video - click here to watch the technical chart video
Yesterday another news source also reported on VXRT. It said:
"Vaxart COVID-19 Tablet Potentially Effective Against New Strains; Shares Soar
2:57 PM ET, 04/27/2021 - MT Newswires
02:57 PM EDT, 04/27/2021 (MT Newswires) -- Vaxart (VXRT) shares rose 38% after saying it will present new mucosal antibody data and review the recent phase I clinical results that suggest its VXA-CoV2-1 tablet is potentially protective against new and emerging COVID-19 strains.
At a May 3 webinar, the company's management will provide new data comparing the T-cell responses generated from its vaccine with those of other vaccines, according to a Tuesday news release.
Price: 8.39, Change: +2.33, Percent Change: +38.37"
awesome pumpy&dumpy $VXRT for 100% gains weeeeeee $$$$$$
I think the big move up on the 27th has to do with the press release issued on April 26, 2021 at 8:00 AM EDT, called "Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines". It says in part: "Vaxart to provide new data from its Phase I COVID-19 trial ... it will host a webinar on the importance of T-cell responses for COVID-19 vaccines on Monday, May 3, 2021 at 12:00 p.m. Eastern Time. ... Vaxart's management will provide new data comparing the T-cell responses generated from its VXA-CoV2-1 vaccine with those of other vaccines. The Company will also present new mucosal antibody data and review the recent Phase I clinical results that suggest VXA-CoV2-1 is potentially protective against new and emerging COVID-19 strains." See https://investors.vaxart.com/news-releases/news-release-details/vaxart-host-key-opinion-leader-webinar-importance-t-cell for the full press release.
See also the article (from after hours on the 27th) called " VXRT Stock: The Big Vaccine News Sending Vaxart Soaring Today - VXRT stock is rocketing upward today as it announces a coming presentation of its newest trial data". That article says in part:
"Investors are becoming bullish as they expect promising data from the company when comparing T-cell therapy to other vaccines. They expect to hear from Vaxart that the particular therapy is potentially effective at proactively targeting emerging strains of Covid-19.
The announcement is driving huge movement of VXRT stock today."
I think the press release is a good sign of progress by Vaxart.
* * $VXRT Video Chart 04-28-2021 * *
Link to Video - click here to watch the technical chart video
Wouldn't be surprised at all, nothing like a Motley Fool "it might go up" article to kick up some liquidity.
Great movement today and more in the after hours.
* * $VXRT Video Chart 04-27-2021 * *
Link to Video - click here to watch the technical chart video
My crystal ball is showing another capital raise any minute, ya think! oh the promiscuity...
Link please?
Where is that info on Icahn taking a stake.
ohh VXRT I lov U $$$$ Gulfstream IV jet $20,000,000, Mansions, and money evrywhere in the world $ 50,000,000, watching kimchi and I laughing at poor man ... priceless hahha yeah I like that mcdonalds comercial to
I think many Covid plays are old news ... with that said , This is interesting .. I'm in with 1000 shares
Probably the Motley Fool spec article with a heavy dose of twitter FOMO:
https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
The idea of a COVID pill is unique, but the whole world will be vaccinated by the time they're done with trials, and that presumes it would work, which is a risk in itself.
This is good info.
But I can't help but to take notice. A WHOLE YEAR, before completion?!?
Where is the governments intervention in this?!? I would like to think that Operation WARP speed should still be a thing. Given that we don't seem to have the optimal solution for the virus, and there continue to be variations surfacing.
But, I think the big players in the game want their head start, so they will get it. Moderna was a fresh company going public in 2019, fast-tracked and now a superstar in the game. Wonder how that happens...
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)
Followers
|
186
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6214
|
Created
|
01/12/05
|
Type
|
Free
|
Moderators |
The Vaxart tablet vaccine is composed of three basic elements:
The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut
The antigen: the pathogen protein designed to trigger the targeted immune response
The adjuvant: a “booster” molecule that stimulates and adds to the immune response
By using the same vector, but with different antigens, Vaxart has designed a modular, scalable and standardized approach to vaccine development.
With this system, we can support the rapid development of numerous vaccines against established targets, as well as against new and emerging pathogens.
We can achieve important synergies – we can use the same manufacturing processes for all of our vaccines.
Norovirus
Three Phase 1 studies of Vaxart’s norovirus tablet vaccine indicated it is well tolerated and generated systemic and local immune responses that are both robust and persistent. The most recent Bivalent Phase 1b study demonstrated subjects obtained robust responses to both the mucosal and the systemic immune system.
Influenza
Influenza is a worldwide infectious disease, with symptoms that range from mild to life-threatening and sometimes resulting in death. Serious illness occurs not only in susceptible populations, such as older adults, but also in the general population when unique strains of influenza arise.
Respiratory Syncytial Virus (RSV)
Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of respiratory infection. While RSV infections can occur at any age, the elderly and those immunocompromised and living with underlying cardiopulmonary disease are particularly vulnerable.
Human Papillomavirus (HPV)
HPV is a group of more than 100 related DNA viruses that have the ability to infect the skin or mucous membranes. HPV is the most common sexually transmitted virus in the U.S. and infection is very prevalent following the onset of sexual activity. Vaxart is targeting HPV infection that causes cervical dysplasia and cancer due to HPV 16 and 18.
Vaxart’s COVID-19 Vaccine Selected
for the U.S. Government’s Operation Warp Speed
June 26, 2020 at 8:00 AM EDT
OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates
SOUTH SAN FRANCISCO, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate.
“We are very pleased to be one of the few companies selected by Operation Warp Speed, and that ours is the only oral vaccine being evaluated. SARS-CoV-2, the coronavirus that causes COVID-19, is primarily transmitted by viral particles that enter through the mucosa - nose, mouth or eyes - strongly suggesting that mucosal immunity could serve as the first line of defense,” said Andrei Floroiu, Chief Executive Officer of Vaxart Inc. “In addition, our vaccine is a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns.”
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been filed with the US Food and Drug Administration (FDA).
“We are very excited to reach this important milestone in advancing our oral COVID-19 vaccine candidate towards the clinic,” said Andrei Floroiu, chief executive officer of Vaxart. “We expect our upcoming Phase I study to generate data that will further differentiate our oral vaccine from injectable vaccines by substantiating the importance of activating both systemic and mucosal immunity in protecting against COVID-19. We believe that this mechanistic benefit combined with the significant advantages of oral administration to the patient while eliminating the need for cold chain distribution, could make our COVID-19 vaccine an ideal candidate for successful mass vaccination campaigns globally.”
“Filing the IND is the first major step of many we are taking to advance our oral vaccine in the prevention of COVID-19,” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “We are excited to be moving this project toward clinical trials, and potentially demonstrating similarly potent mucosal and systemic immune responses like we have seen with our other vaccine candidates using the same oral tablet vaccine platform.”
Emergent BioSolutions Signs Development and Manufacturing Agreement
with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease
GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Development services will begin immediately, and upon Vaxart’s election, Emergent agrees to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.
VXRT Investor Relations
F.D.A. great read KindredBio Partners with Vaxart for COVID-19 Oral Vaccine
October 9, 2020
https://www.fdanews.com/articles/199454-kindredbio-partners-with-vaxart-for-covid-19-oral-vaccine
$VXRT THEN 1. Oral formulations vs Liquid inoculations
[remember $KIN has partnered wit $VXRT]
https://www.fool.com/investing/2020/08/13/3-reasons-doctors-will-prefer-vaxarts-coronavirus/
1. Oral formulations make for easier storage and transport
When most people think of vaccines, they think of a syringe filled with liquid which is administered by a healthcare worker into the muscles or veins of the patient.
In contrast, Vaxart's technology platform produces oral tablets containing the equivalent active components.
This may seem like a minor distinction,
but it's actually a critical factor that works strongly to Vaxart's advantage when it comes to currying favor with doctors and other providers.
Liquid inoculations typically require refrigeration during manufacturing, shipping, and storage at the point of use.
If they aren't consistently kept at the correct temperature, their efficacy may drop, or they may spoil completely.
This means that traditional liquid vaccines imply a substantial logistical burden on healthcare systems,
as well as their suppliers, as a result of the additional refrigeration hardware and energy expenditures required.
Vaxart's tablets are stable at room temperature, however,
so healthcare systems won't need to spend nearly as much to transport or store its coronavirus prophylactic,
and the risk of spoilage is much low
2. Tablets don't require any consumables to administer
When patients get an inoculation in tablet form, there's no need
for the clinic that distributed it to purchase additional disposable syringes, sterilizing swabs, bandages, or even gloves.
As a bonus, after the patient has taken the vaccine, clinics won't
need to pay for additional biohazard trash removal services to dispose of the used materials.
Thanks to the sum of these savings, healthcare systems won't need to spend as much to administer Vaxart's candidate as they might with a traditional liquid inoculation,
enabling them to vaccinate more patients than they could otherwise.
If these savings seem like they might be trivial, consider that an effective coronavirus prophylactic program would need to be deployed
to about 3 billion people globally,
which could easily create shortages and price spikes for the basic healthcare materials or services required for traditional liquid vaccinations.
3. Less risky self-administration
You've probably taken pills without a doctor or nurse standing at
your side to supervise,
but it's unlikely that you've ever prepared and self-injected a vaccination on your own.
With an oral tablet, Vaxart hopes that patients will have the freedom
to vaccinate themselves in the safety of their homes.
This would be particularly advantageous because it would nullify the risk of patients getting infected in crowded clinics while waiting for their turn to be inoculated.
Vaxart's inoculations win via superior logistics, but oral vaccines aren't for everyone
Vaxart's shelf-stable, syringe-free, and easy-to-deploy prophylactic tablets would thus be popular among clinicians around the world thanks to their lower costs,
and savvy investors should recognize that these advantages could be decisive for future earnings.
However, there is one reason why doctors in underdeveloped regions might not favor Vaxart's candidate.
While the scientific consensus is still forming,
it may be the case that malnutrition makes oral vaccination less effective compared with intramuscular vaccination, especially in children.
Therefore, clinics in areas with low food security might opt for a traditional formulation instead of Vaxart's solution.
Even with this potential disadvantage, I think that the vaccine's logistical strengths -- should it be approved
-- will give the company an enduring advantage over the competition.
Time will tell whether Vaxart's coronavirus candidate can live up
to the necessary medical standards. In the meantime, look for the company's phase 1 clinical trial to start later in the summer.
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
The Motley Fool has a disclosure policy.
https://www.otcmarkets.com/stock/VXRT/disclosure
https://www.otcmarkets.com/stock/VXRT/security
https://www.otcmarkets.com/stock/VXRT/profile
https://www.otcmarkets.com/stock/VXRT/quote
https://www.otcmarkets.com/stock/VXRT/overview
PER MGMT DAVE -
IH Geek [Dave] DISCLAIMER |
01-31-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |